Navigation Links
Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
Date:2/20/2008

SOUTH SAN FRANCISCO, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has earned a preclinical milestone payment from Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) under the companies' drug discovery collaboration agreement.

The two companies entered into a research collaboration in May 2002 to discover oral small molecule enzyme inhibitors for the treatment of major chronic inflammatory and autoimmune diseases. The recent milestone payment was triggered by J&JPRD's selection of a compound targeting the Cathepsin S enzyme as a development candidate. Under the terms of the collaboration agreement, Sunesis has the potential to receive additional development milestone payments from J&JPRD, as well as royalty payments based on future product sales.

"We believe that a small molecule inhibitor of Cathepsin S will provide a useful approach to treating certain inflammatory conditions and we are pleased by J&JPRD's advancement of a compound from our collaboration into development," said Bob McDowell, Ph.D., Vice President of Research at Sunesis.

About Cathepsin S

Cathepsin S is an enzyme involved in the activation of immune system T-cells. Inhibiting inappropriate activation of T-cells may lead to novel treatments of certain inflammatory and autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
2. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
4. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
5. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
6. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
7. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
8. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
9. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
10. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...w York investment bank KTA Capital,s client Neuren...7 mil convertible note private placement with a U....as arranged by KTA Capital as Neuren,s exclusive p... New York (PRWEB) November 23, 2009 -- The ind... ("KTA Capital") has announced that its ...
(Date:11/24/2009)...re-FirstCall/--Sigma-AldrichCorporation(Nasdaq: SI...day,December1stat1:45PMGMTinLondon,7:45AMUS/CST.In...heInternetavailableat http://inve s tor.sig m ...toaccessthisfile. ,, AboutSigma-Aldrich: Sig...mpany.Itschemicalandbiochemicalproductsandkitsareu...
(Date:11/24/2009)...RNewswire-FirstCall/--NeurogesX,Inc.(Nasdaq: NGSX ...ommercializingnovelpainmanagementtherapies,announc...veOfficer,isscheduledtopresentatthe21stAnnualPiper...09atTheNewYorkPalaceHotelinNewYork,NewYork. ,, ...r,willbeavailabletorespondtoquestionsduringthepres...
(Date:11/24/2009)...asbeenmetforpatientswithadvanced-stage,orrecurrent...wire-FirstCall/-AEternaZentarisInc.(NASDAQ: AEZS ;...panyfocusedonendocrinetherapyandoncology,todayanno...rgetedcytotoxicpeptideconjugate,AEZS-108(formerlyA...lcancer.Inapersonalizedhealthcareapproach,thestudy...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...TON, July 29 Scimitar Equity, LLC issues a review...ard: VOQP), entitled, "510k,Application Submitted ...cta(TM) Focuses Milestones and Share Price Appreci...tp://www.scimitarequity.com ., VioQuest Pharmaceu...,dedicated to becoming a recognized leader in the ...
... CARLOS, Calif., July 29 Nuvelo, Inc.,(Nasdaq: N...st subject in a,single-center, Phase 1 trial of re...lead compound from its Wnt Therapeutics Program. T...ding dose (SAD) trial will,determine the safety, t...ous (IV) administration of NU206, in approximately...
... "As one of AFRA,s fou...ceive its accreditation," remarks Gregoire Le... "For more than 10 years our vision in the gl...n, JMV Aviation and BAR) has been to operate in a ... to our five locations in France as well as facili...
Other Biology Technology:VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC 2Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers 2Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers 3First Program Addressing Aircraft Industry Sustainability Awards Accreditation To Five Global Companies 2First Program Addressing Aircraft Industry Sustainability Awards Accreditation To Five Global Companies 3First Program Addressing Aircraft Industry Sustainability Awards Accreditation To Five Global Companies 4
(Date:11/24/2009)...ousands of years it has been prescribed by traditi...s from headaches and stomach pain to fever and flu...tle University have been able to scientifically pr...ta otherwise known as Brazilian mint. , Testing...m led by researcher Graciela Rocha was able to sho...
(Date:11/24/2009)... that keep weakened and flabby arteries from colla...nths, those stents are no longer needed -- once th...ry. Previously, doctors had no choice but to leave...Aviv University,s Department of Biomedical Enginee...form that carries drugs where they,re needed, then...
(Date:11/24/2009)...N ROUGE Antarctica has long held secrets of the e... recently, there has been very little information ...miles of ice for millions of years. Now, a team of... have been funded to the tune of $10 million doll... get to the bottom of things literally. These sci...
Breaking Biology News(10 mins):Got a pain? -- Have a cup of Brazilian mint 2A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 1Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 2Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 3Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 4Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 5Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 1Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 2Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 3China Pharma Holdings Inc Announces SFDA Approval for Rosuvastatin Clinical Trials 49581 1China Pharma Holdings Inc Announces SFDA Approval for Rosuvastatin Clinical Trials 49581 2China Pharma Holdings Inc Announces SFDA Approval for Rosuvastatin Clinical Trials 49581 3
...n a mud flat at the edge of the Cocheco River, jus...ersity of New Hampshire,s Contaminated Sediments C...ted sediment in coastal waterways. , Rather than ...al feet of sand, they,ve created a patch black ge...ion in place. Over the next two years, UNH associa...
... is available in German . , Infectious proteins... of "mad cow" disease (BSE). The culprits are "inc...y proteins. The molecular bases for such prion dis...roteins infectious while others are not? A team he...aimon Sabat (University of Bordeaux, France) has e...
...f., June 16 Authernative, Inc., a,leading develop...management,technologies, announced today that it h...n (GSA) Information Technology Schedule contract, ...tive to sell its AuthGuard(R),user authentication ... Schedule contract, which represents Authernative,...
Other Biology News:UNH researchers test sediment-scrubbing technology in NH river 2UNH researchers test sediment-scrubbing technology in NH river 3Tracking prions 2Authernative Awarded GSA Schedule Contract 2Authernative Awarded GSA Schedule Contract 3
RDF (R106-05) from European Collection of Cell Cultures (ECACC)
...The Brownlee Precision Model 440 incorporates four...rcuitry in a friendly easy-to-use instrument. Each...er, an 8-pole Bessel lowpass filter, a highpass fi...ols. A control knob sets the amplifier parameters ...
REK (R102-05) from European Collection of Cell Cultures (ECACC)
PCAEC (P300-05) from European Collection of Cell Cultures (ECACC)
Biology Products: